Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Jason A Keyes is Chief Financial Officer at Equillium. OQRO lists 3 transactions filed with the SEC under this name, the latest on May 23, 2026, each linked to the official Form 4.
Chief Financial Officer
Disclosures on record
3
Companies involved
2
As of the latest filing on , Jason A Keyes reported holding 37,720 shares of Equillium (EQ), worth about $49K at the last close of $1 (Nov 13, 2026), held through a keyes trust dated september 10, 2004. Holdings are also on file at Blossomhill Therapeutics (BLSM); together they are worth about $58K.
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Equillium EQ | 37,720 | 38K keyes trust dated september 10, 2004 | $1 | $49K | Jan 23, 2025 |
| Blossomhill Therapeutics BLSM | 700 | 700 direct | $14 | $9.8K | Aug 10, 2026 |
Is this Jason A Keyes’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
1 buy, median −10.2 pts vs S&P 500, beat it 0 of 1 time.
Average −10.2 pts vs S&P 500. Each buy is one disclosure of open-market purchases in one company on one filing date, filed Aug 10, 2026 to Aug 10, 2026, measured from the first close after the filing. Past results, not a forecast.
1 purchase disclosed; 0% of the 1 measured at 90 days finished ahead of the index. $1,000 placed after each of the 1 purchases disclosed since 2025-11-14 would be worth $849 today ($1K put in); the same in the S&P 500 (SPY): $979.
Not ranked: fewer than 10 purchases measured at 90 days. The middle of the 82 ranked insiders is −5.5 pts (median, against the S&P 500).
Equal weight counts every purchase once; by size counts it for its disclosed dollars. Both are measured from the first close after it was reported. Past results describe the past, not a forecast. How this is measured · Leaderboard
May 21, 202615Kdisclosed May 23
DetailsOfficial recordEquilliumEQ
2 disclosures · Nov 2024 – Jan 2025 · 2 sold
Jan 23, 2025Sold~$6.5Kdisclosed Jan 24
DetailsOfficial recordNov 14, 2024Sold~$7Kdisclosed Nov 15
DetailsOfficial recordJason A Keyes has no open-market purchase on record since 2019. Sales in 6 of the 8 years since 2019.
Jason A Keyes reported 0 open-market purchases and 16 sales since 2019; no open-market purchase.
| Year | Bought | Sold |
|---|---|---|
| 2025 | — | $6.5K1×1 trade |
| 2024 | — | $24K3×3 trades |
| 2022 | — | $58K3×3 trades |
| 2021 | — | $140K4×4 trades |
| 2020 | — | $85K3×3 trades |
| 2019 | — | $38K2×2 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
On the latest SEC Form 4, dated Jan 23, 2025, Jason A Keyes reported holding 37,720 shares of Equillium (EQ), held indirectly. At the last close of $1 on Nov 13, 2026, that is about $49K. This is the stake disclosed in filings, not a net worth.
Jason A Keyes has no open-market purchase on record since 2019. Sales in 6 of the 8 years since 2019.
In SEC filings since 2019: no open-market purchase is on record; the latest open-market sale is from 2025.
Equillium (EQ), from 2019 to 2025: 0 purchases and 16 sales.
Jason A Keyes reported 0 open-market purchases and 16 sales here, 2019 to 2025.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
